EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC 4.0

Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours

Yuehua Li, Chengjiang Wei, Wei Wang, Qingfeng Li, Zhi-Chao Wang iD

The Journal of Pathology: Clinical Research · 2023-03 · 9 (2) · 89-99

DOI: 10.1002/cjp2.307 ↗

At a glance

Übersichtsarbeit in The Journal of Pathology: Clinical Research, published online on 2022-12-19. Written by Yuehua Li and 4 co-authors. Institution: Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR Ch…. Major MEDLINE topics: Receptor, trkB, Neoplasms. Cited 22 times so far (Crossref); 108 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: National Natural Science Foundation of China, Natural Science Foundation of Shanghai, Science and Technology Commission of Shanghai Municipality.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Tropomyosin receptor kinase B (TrkB), a transmembrane receptor protein, has been found to play a pivotal role in neural development. This protein is encoded by the neurotrophic receptor tyrosine kinase 2 ( NTRK2 ) gene, and its abnormal activation caused by NTRK2 overexpression or fusion can contribute to tumour initiation, progression, and resistance to therapeutics in multiple types of neurogenic tumours. Targeted therapies for this mechanism have been designed and developed in preclinical and clinical studies, including selective TrkB inhibitors and pan‐TRK inhibitors. This review describes the gene structure, biological function, abnormal TrkB activation mechanism, and current‐related targeted therapies in neurogenic tumours.

Subjects

MeSH terms (MEDLINE)

Receptor, trkBNeoplasmsHumansReceptor, trkAReceptor, trkCTropomyosinMembrane GlycoproteinsMembrane Proteins

Author keywords

NTRKTrkBabnormal activationgene fusionneurogenic tumourstargeted therapytyrosine kinase

Substances

Receptor, trkBReceptor, trkAReceptor, trkCTropomyosinMembrane GlycoproteinsMembrane Proteins

Authors and institutions

  • Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.

ORCID profiles: Zhi-Chao Wang

Funding

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shanghai
  • Science and Technology Commission of Shanghai Municipality

Cite

APA

Li, Y., Wei, C., Wang, W., Li, Q., & Wang, Z. C. (2023). Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours. The Journal of Pathology: Clinical Research, 9(2), 89-99. https://doi.org/10.1002/cjp2.307

Vancouver

Li Y, Wei C, Wang W, Li Q, Wang ZC. Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours. The Journal of Pathology: Clinical Research. 2023;9(2):89-99. doi:10.1002/cjp2.307

BibTeX
@article{Li2023,
  author = {Li, Yuehua and Wei, Chengjiang and Wang, Wei and Li, Qingfeng and Wang, Zhi-Chao},
  title = {Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2023},
  volume = {9},
  number = {2},
  pages = {89--99},
  doi = {10.1002/cjp2.307}
}
Start for free →